Berenguer, 3,995 patient HCQ late treatment study: 18% lower mortality [p=0.0001] https://c19p.org/berenguer
copied to clipboard
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.07.024
Retrospective 4035 hospitalized patients in Spain showing reduced mortality with HCQ (data is in the supplementary appendix).
|
risk of death, 18.2% lower, RR 0.82, p < 0.001, treatment 681 of 2,618 (26.0%), control 438 of 1,377 (31.8%), NNT 17.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Berenguer et al., 8/3/2020, retrospective, Spain, Europe, peer-reviewed, 8 authors, average treatment delay 7.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.